GSK's Financial Growth in Q1 2023

GSK plc has announced a notable 2% increase in its first-quarter turnover for 2023, reaching £6.95 billion compared to the same period in 2024. When adjusted for constant exchange rates, this growth improves to 4%.

Earnings and Profit Surge

The company's total earnings per share (EPS) experienced a significant 55% year-on-year increase to 39.7 pence, with core EPS also rising by 4% to 44.9 pence. Operating profit saw a remarkable 49% surge to £2.2 billion, and adjusted operating profit increased by 4% to £2.5 billion.

Strategic Progress and Future Outlook

"GSK is making strong progress, showcasing the quality, strength, and resilience of our portfolio," stated CEO Emma Walmsley. She highlighted the strong sales contributions from Specialty Medicines, advancements in R&D, and the acquisition of a promising new oncology asset. The company is also focusing on preparing for the launches of Blenrep, Nucala, and depemokimab, alongside pivotal trials for potential new medicines in respiratory, oncology, HIV, and hepatitis.